The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Phase 1 has already been executed with the construction of temporary OPD, guest house and boundary wall and Phase 2 of the execution is being fast tracked
Investment in response to increased demand for North American-based chemistry services
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
Govt. has set a target to increase the number of JanAushadhi Kendras to 10,000 by March 2024
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
India has the second-largest number of adults with diabetes globally, after China
Subscribe To Our Newsletter & Stay Updated
